Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development
- PMID: 17762886
- DOI: 10.1038/nrd2379
Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development
Abstract
Muscarinic acetylcholine receptors (mAChRs), M(1)-M(5), regulate the activity of numerous fundamental central and peripheral functions. The lack of small-molecule ligands that can block or activate specific mAChR subtypes with high selectivity has remained a major obstacle in defining the roles of the individual receptor subtypes and in the development of novel muscarinic drugs. Recently, phenotypic analysis of mutant mouse strains deficient in each of the five mAChR subtypes has led to a wealth of new information regarding the physiological roles of the individual receptor subtypes. Importantly, these studies have identified specific mAChR-regulated pathways as potentially novel targets for the treatment of various important disorders including Alzheimer's disease, schizophrenia, pain, obesity and diabetes.
Comment in
-
M3 muscarinic receptors as targets for drug development in neurodegenerative disorders.Nat Rev Drug Discov. 2008 Feb;7(2):1 p following p185. doi: 10.1038/nrd2506-c1. Nat Rev Drug Discov. 2008. PMID: 18246605 No abstract available.
Similar articles
-
Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications.Annu Rev Pharmacol Toxicol. 2004;44:423-50. doi: 10.1146/annurev.pharmtox.44.101802.121622. Annu Rev Pharmacol Toxicol. 2004. PMID: 14744253 Review.
-
Novel insights into muscarinic acetylcholine receptor function using gene targeting technology.Trends Pharmacol Sci. 2003 Aug;24(8):414-20. doi: 10.1016/S0165-6147(03)00195-0. Trends Pharmacol Sci. 2003. PMID: 12915051 Review.
-
Muscarinic acetylcholine receptors as CNS drug targets.Pharmacol Ther. 2008 Feb;117(2):232-43. doi: 10.1016/j.pharmthera.2007.09.009. Epub 2007 Dec 20. Pharmacol Ther. 2008. PMID: 18082893 Review.
-
Novel muscarinic receptor mutant mouse models.Handb Exp Pharmacol. 2012;(208):95-117. doi: 10.1007/978-3-642-23274-9_6. Handb Exp Pharmacol. 2012. PMID: 22222697 Review.
-
Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.Trends Pharmacol Sci. 2009 Mar;30(3):148-55. doi: 10.1016/j.tips.2008.12.002. Epub 2009 Feb 7. Trends Pharmacol Sci. 2009. PMID: 19201489 Free PMC article. Review.
Cited by
-
Identification of Antagonistic Action of Pyrrolizidine Alkaloids in Muscarinic Acetylcholine Receptor M1 by Computational Target Prediction Analysis.Pharmaceuticals (Basel). 2024 Jan 8;17(1):80. doi: 10.3390/ph17010080. Pharmaceuticals (Basel). 2024. PMID: 38256913 Free PMC article.
-
Muscarinic receptors modulate the intrinsic excitability of infralimbic neurons and consolidation of fear extinction.Neuropsychopharmacology. 2012 Aug;37(9):2047-56. doi: 10.1038/npp.2012.52. Epub 2012 Apr 18. Neuropsychopharmacology. 2012. PMID: 22510723 Free PMC article.
-
G-Protein-Coupled Receptors and Ischemic Stroke: a Focus on Molecular Function and Therapeutic Potential.Mol Neurobiol. 2021 Sep;58(9):4588-4614. doi: 10.1007/s12035-021-02435-5. Epub 2021 Jun 12. Mol Neurobiol. 2021. PMID: 34120294 Review.
-
A muscarinic view on Gq.Naunyn Schmiedebergs Arch Pharmacol. 2013 Nov;386(11):935-6. doi: 10.1007/s00210-013-0895-7. Naunyn Schmiedebergs Arch Pharmacol. 2013. PMID: 23779215 No abstract available.
-
Design, Synthesis, and Biological Evaluation of 4,4'-Difluorobenzhydrol Carbamates as Selective M1 Antagonists.Pharmaceuticals (Basel). 2022 Feb 18;15(2):248. doi: 10.3390/ph15020248. Pharmaceuticals (Basel). 2022. PMID: 35215360 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases